SPESN38-8
/ Sunstate Biosciences
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 18, 2026
Single protein encapsulated SN38: Extremely effective anticancer drug with low toxicity
(AACR 2026)
- "At present, only prodrug approach on SN38 has resulted in 2 types of therapeutics approved by the FDA, irinotecan/ONIVYDE and Trodelvy...Therefore, novel approaches are urgently needed for effectively delivering SN38. Our patented single protein encapsulation (SPE) platform, allowing encapsulation of small-molecule drugs by a single protein (albumins or globulins) without artificial nanoparticles and chemical modifications to drugs and proteins, has made the first drug product, SPEDOX-6 into human phase IB/IIA clinical trial (NCT0764018)... SPESN38 complexes provide a novel water soluble SN38 formulation. SPESN38‑5 and SPESN38‑8 demonstrate better PK values, lower toxicity and superior antitumor efficacy in mouse models, compared with irinotecan, DOX and Doxil. FDA has green-lighted SPESN38-8 (IND #: 164346) for clinical development."
Colorectal Cancer • Ewing Sarcoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor
March 18, 2026
Antibody encapsulated drug: Tr-ACT2 for targeted treatments of various cancers
(AACR 2026)
- "Trastuzumab (Tr) has demonstrated efficacy in treatment of HER2+ breast cancer and advanced gastric cancer. Recently, Tr-based antibody drug conjugates (ADCs), Kadecyla and Enhertu, have emerged as a new class of anti-HER2 therapies by combining targeted antibodies with cytotoxic agents via linkers...Therefore, smarter and more efficient designs are urgently needed. Our patented single protein encapsulation (SPE) platform, allowing encapsulation of small-molecule drugs by a single protein (albumins or globulins) without artificial nanoparticles and chemical modifications to drugs and proteins, has achieved great success in development of 2 drug products, SPEDOX-6 under human clinical trial (NCT0764018) and SPESN38-8 (IND #: 164346) under IND-enabling study based on albumin, which have prompted us to utilize antibody, such as Tr to encapsulate cytotoxic payload, actinomycin D (ACT, RNA polymerase inhibitor), forming antibody encapsulated drugs (AEDs)... We have developed..."
Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1